Showing 1 - 10 of 12,027
Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our...
Persistent link: https://www.econbiz.de/10012604733
This paper evaluates the effects of patent protection on pharmaceutical innovations for twenty-six countries that established pharmaceutical patent laws during 1978-2002. Controlling for country characteristics through matched sampling techniques to establish two proper comparison sets among...
Persistent link: https://www.econbiz.de/10012751759
Persistent link: https://www.econbiz.de/10014463953
Persistent link: https://www.econbiz.de/10012433847
Persistent link: https://www.econbiz.de/10012433548
The COVID-19 crisis intensified decade-long debates on the interaction between intellectual property rights (IPRs), competition law and access to affordable life-saving treatments and vaccines. Compulsory licensing of patented medicines is a tried-and-tested method to expand access, particularly...
Persistent link: https://www.econbiz.de/10014541546
Persistent link: https://www.econbiz.de/10003561395
Persistent link: https://www.econbiz.de/10012433661
Persistent link: https://www.econbiz.de/10010428669